CoChat

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations

Open access
Grainger, Rebecca, Kim, Alfred H. J., Conway, Richard, Yazdany, Jinoos, Robinson, Philip C. · 2022 · Nature Reviews Rheumatology
Cited by 188

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

The COVID-19 pandemic has brought challenges for people with rheumatic disease in addition to those faced by the general population, including concerns about higher risks of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and poor outcomes of COVID-19. The data that are now available suggest that rheumatic disease is associated with a small additional risk of SARS-CoV-2 infection, and that outcomes of COVID-19 are primarily influenced by comorbidities and particular disease states or treatments. Despite considerable advances in our knowledge of which therapeutic agents provide benefits in COVID-19, and of what constitutes effective vaccination strategies, the specific considerations that apply to people with rheumatic disease are yet to be definitively addressed. An overview of the most important COVID-19 studies to date that relate to people with rheumatic disease can contribute to our understanding of the clinical-care requirements of this population. In this Review, the authors summarize the current knowledge relating to SARS-CoV-2 infection and the prevention and treatment of COVID-19 in people with rheumatic disease. People with immune or inflammatory rheumatic disease might have a higher risk of infection with SARS-CoV-2 after exposure than the general population, although the additional risk is probably small. Risk of poor COVID-19 outcomes in patients with rheumatic disease seems to be mediated by the presence of comorbidities, treatment with glucocorticoids or rituximab, and high disease activity. People with immune or inflammatory rheumatic disease who experience mild COVID-19 symptoms should stop taking immunomodulating medications for 1–3 weeks from the onset of disease. People with rheumatic disease with positive SARS-CoV-2 test results or mild COVID-19 symptoms and risk factors for poor outcomes should stop taking immunomodulating medications and consider treatment with antiviral medications. Most patients with treated rheumatic disease generate antibody responses to SARS-CoV-2 vaccines, but medications such as B cell-depleting therapies and mycophenolate confer a high risk of poor responses. People with immune or inflammatory rheumatic disease are strongly recommended to receive SARS-CoV-2 vaccination, including booster doses if recommended, despite some evidence of a diminished response in particular groups. People with immune or inflammatory rheumatic disease might have a higher risk of infection with SARS-CoV-2 after exposure than the general population, although the additional risk is probably small. Risk of poor COVID-19 outcomes in patients with rheumatic disease seems to be mediated by the presence of comorbidities, treatment with glucocorticoids or rituximab, and high disease activity. People with immune or inflammatory rheumatic disease who experience mild COVID-19 symptoms should stop taking immunomodulating medications for 1–3 weeks from the onset of disease. People with rheumatic disease with positive SARS-CoV-2 test results or mild COVID-19 symptoms and risk factors for poor outcomes should stop taking immunomodulating medications and consider treatment with antiviral medications. Most patients with treated rheumatic disease generate antibody responses to SARS-CoV-2 vaccines, but medications such as B cell-depleting therapies and mycophenolate confer a high risk of poor responses. People with immune or inflammatory rheumatic disease are strongly recommended to receive SARS-CoV-2 vaccination, including booster doses if recommended, despite some evidence of a diminished response in particular groups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41584-022-00755-x

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Metadata

Authors
Grainger, R., Kim, A. H. J., Conway, R., Yazdany, J., & Robinson, P. C.
Venue
Nature Reviews Rheumatology
Published
2022-02-25
Volume
18
Issue
4
Pages
191-204
ISSN
  • 1759-4790 (ISSN-L)
  • 1759-4804
OpenAlex
W4214501619
Cited by
188
References
30
FWCI
8.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. https://app.cochat.ai/papers/10.1038/s41584-022-00755-x
The paper
Grainger, R., Kim, A. H. J., Conway, R., Yazdany, J., & Robinson, P. C. (2022). COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-022-00755-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.